David Nierengarten
Stock Analyst at Wedbush
(3.70)
# 739
Out of 4,944 analysts
199
Total ratings
44.23%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Maintains: Outperform | $31 → $26 | $8.15 | +219.02% | 7 | Aug 7, 2025 | |
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $2.04 | -80.39% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $639.34 | +11.83% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.96 | +177.78% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.99 | +100.16% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $2.49 | +100.80% | 9 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.10 | +18.81% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $11.36 | -11.97% | 10 | May 19, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $11.59 | +132.96% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $33.37 | +1.90% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $10.25 | +221.95% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.79 | +152.72% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.19 | +320.17% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $11.09 | +179.53% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $20.22 | +97.82% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $36.91 | +143.84% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $32.53 | +44.48% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $77.28 | +48.81% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.52 | +170.11% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.09 | +98.22% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.78 | +170.64% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $16.88 | +166.59% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.74 | +476.37% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.53 | +611.46% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $60.40 | -5.62% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $5.91 | +746.02% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.02 | -16.81% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.68 | +226.09% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.47 | +226.27% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $6.24 | +2,704.49% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.65 | +13,598.63% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.30 | +1,295.35% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $9.20 | +106.52% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $28.48 | +163.34% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.65 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.06 | - | 3 | Nov 20, 2017 |
Xencor
Aug 7, 2025
Maintains: Outperform
Price Target: $31 → $26
Current: $8.15
Upside: +219.02%
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $2.04
Upside: -80.39%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $639.34
Upside: +11.83%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.96
Upside: +177.78%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $10.99
Upside: +100.16%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $2.49
Upside: +100.80%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.10
Upside: +18.81%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $11.36
Upside: -11.97%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $11.59
Upside: +132.96%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $33.37
Upside: +1.90%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $10.25
Upside: +221.95%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.79
Upside: +152.72%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.19
Upside: +320.17%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $11.09
Upside: +179.53%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $20.22
Upside: +97.82%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $36.91
Upside: +143.84%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $32.53
Upside: +44.48%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $77.28
Upside: +48.81%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $8.52
Upside: +170.11%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.09
Upside: +98.22%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $14.78
Upside: +170.64%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $16.88
Upside: +166.59%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.74
Upside: +476.37%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.53
Upside: +611.46%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $60.40
Upside: -5.62%
Aug 8, 2024
Reiterates: Outperform
Price Target: $50
Current: $5.91
Upside: +746.02%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $12.02
Upside: -16.81%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.68
Upside: +226.09%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.47
Upside: +226.27%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $6.24
Upside: +2,704.49%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.65
Upside: +13,598.63%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.30
Upside: +1,295.35%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $9.20
Upside: +106.52%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $28.48
Upside: +163.34%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.65
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.06
Upside: -